SURVIVAL RATE OF BARICITINIB IN A LARGE COHORT OF RHEUMATOID ARTHRITIS PATIENTS: ANALYSIS OF REAL-WORLD DATA in Annals of the Rheumatic Diseases
2023
ASL Novara
AOU Città della Salute di Torino
ASL Cuneo 1
Tipo pubblicazione
Conference Abstract
Autori/Collaboratori (54)Vedi tutti...
Parisi S
Azienda Ospedaliero-Universitaria, Città della Salute e della Scienza di Torino, Department of General and Specialistic Medicine, Turin, Italy
Becciolini A
University Hospital of Parma, Department of Medicine, Internal Medicine and Rheumatology Unit, Parma, Italy
Ditto MC
University Hospital of Parma, Department of Medicine, Internal Medicine and Rheumatology Unit, Parma, Italy
et alii...
Abstract
Background: Recently, the new class of drugs, namely targeted synthetic (ts) DMARDs, has broadened the possibilities of treating rheumatoid arthritis (RA). In particular, Janus Kinase inhibitors (JAKi) are used in RA and are currently represented by four drugs: baricitinib, tofacitinib, upadacitinib and filgotinib. One of the first to be used in Italy was baricitinib, a JAKi acting on JAK1 and JAK2. Objectives: The aim of this study was to evaluate the clinical efficacy of baricitinib in a real-life setting in a cohort of RA patients. Methods: This multicenter retrospective observational study included patients from 25 rheumatology centers diagnosed with RA and treated with baricitinib. The following were recorded for each patient: gender; age; duration of disease; presence of rheumatoid factor and anti-citrulline antibodies; concomitant treatment with conventional synthetic (cs) DMARDs; previous treatments with biological (b) or ts DMARDs. In order to evaluate the clinical efficacy, the retention rate was evaluated, calculated by means of the Kaplan-Meier method. The variables under examination were reported as frequencies and median with relative interquartile range. Results: We included 478 patients of which 380 (79.5%) were female. 286 (60.1%) patients tested positive for rheumatoid factor (RF) and 264 (55,2%) for anti-citrulline antibody (ACPA). The parameters analyzed are shown in Table 1. 105 (22.0%) patients were treated with baricitnib as first line (after csDMARD), the remaining patients had failed at least one bDMARD and 9 (1.9%) also failed a tsDMARD. In 34,7% of cases baricitinib was used as monotherapy, the most frequently used csDMARD was methotrexate (29.2%). The median period of therapy was 674 days (298-1087). The survival rate at 6 months was 94.6%, at 12 months it was 87,9%, at 24 months was 81.7% and at 48 months was 53.4% (Figure 1). The main causes that led to the discontinuation of baricitinib therapy were: primary ineffectiveness (7,3
Se sei accreditato in BVS-P effettua l'accesso per utilizzare i nostri servizi.
DOI : 10.1136/annrheumdis-2023-eular.1445
Keywords
baricitinib; cyclic citrullinated peptide antibody; disease modifying antirheumatic drug; endogenous compound; methotrexate; rheumatoid factor; adult; cohort analysis; comparative effectiveness; conference abstract; controlled study; drug therapy; female; gender; human; Kaplan Meier method; line of treatment; major clinical study; male; monotherapy; multicenter study; observational study; retrospective study; rheumatoid arthritis; rheumatology; steroid therapy; survival rate; treatment failure;